<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>HER3-targeted therapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/her3-targeted-therapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 27 Nov 2023 17:48:14 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>HER3-targeted therapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Phase II Clinical Study Results of the HERTHENA-Lung01 Study</title>
		<link>https://bioengineer.org/phase-ii-clinical-study-results-of-the-herthena-lung01-study/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 27 Nov 2023 17:47:15 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[cancer research]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[EGFR-mutant NSCLC]]></category>
		<category><![CDATA[HER3-DXd]]></category>
		<category><![CDATA[HER3-targeted therapy]]></category>
		<category><![CDATA[late-stage treatment]]></category>
		<category><![CDATA[lung cancer therapy.]]></category>
		<category><![CDATA[oncology innovations]]></category>
		<category><![CDATA[patritumab deruxtecan]]></category>
		<category><![CDATA[Phase II Clinical Trial Results of the HERTHENA-Lung01 Studylung cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=217034</guid>

					<description><![CDATA[Lung cancer is one of the most common types of cancer worldwide, and the treatment process for patients with non-small cell lung cancer (NSCLC) carrying EGFR mutations can be particularly complex. This disease is characterized by uncontrolled growth and proliferation of cells in the lungs. The EGFR mutation is considered a significant factor in the [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">217034</post-id>	</item>
	</channel>
</rss>
